Tdose Binding and Tocilizumab

Sponsor
Centre Hospitalier Universitaire de Nice
Study ID
NCT07582185
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Experimental: dose binding arm — DRUG
    TOCILIZUMAB administered at standardized, fixed-interval doses versus weight-based dosing
  • Active Comparator: traditionnal arm: Weight-based dosing — DRUG
    standart administration; weight-based dosing

Study Details

The investigators aim to evaluate the non-inferiority of administering tocilizumab at a fixed dose versus a weight-based dose in patients with rheumatoid arthritis in remission or with low clinical activity, after 3 months of treatment, as part of a two-center randomized trial.

Key Dates

First listed
May 12, 2026
Start date
Jun 1, 2026
Status verified
May 2026
Primary completion
Sep 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
122 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: dose binding arm
    dose binding arm for tocilizumab
  • Active Comparator: traditionnal arm
    dose weight for tocilizumab

Primary Outcome Measure

disease activity [ Time Frame: month 3 ]

Central Contacts

Find similar trials

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies